A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).
Kathleen Margaret Mahoney
No relevant relationships to disclose
SuChun Cheng
No relevant relationships to disclose
Rupal Satish Bhatt
No relevant relationships to disclose
Mekailah Simpson
No relevant relationships to disclose
Michael B. Atkins
Consultant or Advisory Role - Roche/Genentech
Igor Puzanov
No relevant relationships to disclose
Sabina Signoretti
No relevant relationships to disclose
M Dror Michaelson
Consultant or Advisory Role - Abbott Laboratories (U); AVEO (U); Eisai (U); Millennium (U); Novartis (U); Pfizer (U)
Research Funding - Abbott Laboratories; AVEO; Eisai; Millennium; Novartis; Pfizer
David F. McDermott
Consultant or Advisory Role - Genentech; Pfizer
Toni K. Choueiri
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Pfizer
Research Funding - Pfizer